Dichlorophenol HSD17B13 Inhibitors for Liver Lipid Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) lack effective pharmacological therapies, with HSD17B13 being a key enzyme in lipid accumulation and a potential biomarker for liver diseases, and current treatments rely heavily on lifestyle modifications which are difficult to maintain for obese patients.
Innovation Solution
Development of HSD17B13 inhibitors to reduce its expression or activity, which can be administered in pharmaceutical compositions to treat or prevent liver diseases, metabolic diseases, and cardiovascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifestyle modification by diet and exercise is used as treatment, then health improvement is achieved, but patient compliance is difficult to maintain
Solution Approach 1:
The patent introduces HSD17B13 inhibitors as a pharmacological intermediary that mediates the treatment effect between lifestyle modifications and health outcomes. These inhibitors provide a chemical bridge that can achieve therapeutic effects when lifestyle changes alone are insufficient or难以 to maintain, thus resolving the compliance problem while preserving treatment effectiveness.
2Adaptability or versatility
If HSD17B13 inhibitors are developed, then pharmacological therapy is provided, but drug development complexity increases
Solution Approach 1:
The patent extracts and targets the specific HSD17B13 enzyme as the therapeutic target, separating this specific enzymatic function from the complex metabolic pathways. By focusing on this single enzyme that plays a key role in lipid accumulation, the patent simplifies the drug development process while providing effective pharmacological therapy for NAFLD and related diseases.
Data Source
AI summary
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).